Ra Pharmctl Inc (RARX) Given Average Recommendation of “Buy” by Brokerages
Ra Pharmctl Inc (NASDAQ:RARX) has earned a consensus rating of “Buy” from the six brokerages that are covering the firm, MarketBeat reports. One analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $26.75.
Several equities analysts have recently weighed in on RARX shares. Jefferies Group LLC reaffirmed a “buy” rating and set a $25.00 target price on shares of Ra Pharmctl in a report on Thursday, June 1st. Zacks Investment Research raised shares of Ra Pharmctl from a “hold” rating to a “buy” rating and set a $30.00 price target for the company in a report on Wednesday, May 17th. Finally, Royal Bank Of Canada started coverage on shares of Ra Pharmctl in a report on Thursday. They issued an “outperform” rating for the company.
Shares of Ra Pharmctl (NASDAQ RARX) traded up 5.84% during trading on Thursday, hitting $14.87. 119,396 shares of the company were exchanged. The firm’s 50-day moving average price is $14.25 and its 200 day moving average price is $18.93. Ra Pharmctl has a 12 month low of $12.05 and a 12 month high of $24.12. The firm’s market capitalization is $336.20 million.
Ra Pharmctl (NASDAQ:RARX) last posted its earnings results on Wednesday, August 9th. The company reported ($0.56) earnings per share for the quarter, missing the consensus estimate of ($0.50) by ($0.06). On average, equities research analysts expect that Ra Pharmctl will post ($2.33) earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “Ra Pharmctl Inc (RARX) Given Average Recommendation of “Buy” by Brokerages” was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this piece on another site, it was copied illegally and republished in violation of United States and international trademark and copyright laws. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2017/09/14/ra-pharmctl-inc-rarx-given-average-recommendation-of-buy-by-brokerages.html.
In related news, major shareholder Bioventures Ltd Novartis sold 56,420 shares of the business’s stock in a transaction on Monday, June 19th. The shares were sold at an average price of $21.29, for a total value of $1,201,181.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 14.50% of the stock is currently owned by insiders.
A number of hedge funds and other institutional investors have recently modified their holdings of the stock. The Manufacturers Life Insurance Company increased its holdings in Ra Pharmctl by 30.6% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 10,860 shares of the company’s stock worth $204,000 after acquiring an additional 2,543 shares in the last quarter. TIAA CREF Investment Management LLC grew its holdings in shares of Ra Pharmctl by 97.0% during the first quarter. TIAA CREF Investment Management LLC now owns 7,837 shares of the company’s stock worth $167,000 after buying an additional 3,859 shares in the last quarter. California State Teachers Retirement System grew its holdings in shares of Ra Pharmctl by 26.1% during the second quarter. California State Teachers Retirement System now owns 20,800 shares of the company’s stock worth $390,000 after buying an additional 4,300 shares in the last quarter. Goldman Sachs Group Inc. grew its holdings in shares of Ra Pharmctl by 7.0% during the second quarter. Goldman Sachs Group Inc. now owns 73,103 shares of the company’s stock worth $1,370,000 after buying an additional 4,751 shares in the last quarter. Finally, American International Group Inc. purchased a new stake in shares of Ra Pharmctl during the first quarter worth $102,000. 66.26% of the stock is owned by institutional investors.
About Ra Pharmctl
Ra Pharmaceuticals, Inc is a United States-based clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutics for diseases of complement dysregulation and a range of orphan indications. It utilizes small molecules and peptide approaches to address pathological targets in the complement cascade.
Receive News & Ratings for Ra Pharmctl Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ra Pharmctl Inc and related companies with MarketBeat.com's FREE daily email newsletter.